IN THE CLAIMS

Please amend the claims as follows:

1.(Original) A rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-HT agonist, at least one spheronization aid and at least one solubility enhancer.

2.(Original) The rapid absorption pharmaceutical composition of claim 1 wherein said composition is incorporated into a plurality of microparticles.

3.(Original) The rapid absorption pharmaceutical composition of claim 2 wherein each microparticle is from about 150 μm to about 500 μm in diameter.

4.(Original) The rapid absorption pharmaceutical composition of claim 3 wherein each microparticle is from about 200 μm to about 250 μm in diameter.

5.(Original) The rapid absorption pharmaceutical composition of claim 4 wherein said at least one selective 5-HT agonist is selected form the group consisting of sumatriptan, zolmitriptan, rizatriptan, naratriptan, frovatriptan, eletriptan, almotriptan and any combination thereof.

6.(Original) The rapid absorption pharmaceutical composition of claim 5 wherein said at least one selective 5-HT agonist is sumatriptan.

7.(Original) The rapid absorption pharmaceutical composition of claim 6 wherein said sumatriptan is present in an amount from about 1% to about 60% by weight of each said

microparticle.

8.(Original) The rapid absorption pharmaceutical composition of claim 7 wherein said sumatriptan is present in an amount from about 20% to about 50% by weight of each said microparticle.

9.(Original) The rapid absorption pharmaceutical composition of claim 8 wherein said sumatriptan is present in an amount from about 30% to about 40% by weight of each said microparticle.

10.(Original) The rapid absorption pharmaceutical composition of claim 4 wherein said at least one spheronization aid is selected from the group consisting of distilled monoglycerides, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oils, polyoxyethylene ethers, cetostearyl alcohol, thermo-softening polymers and any combination thereof.

11.(Original) The rapid absorption pharmaceutical composition of claim 10 wherein said at least one spheronization aid is glyceryl palmitostearate.

12.(Original) The rapid absorption pharmaceutical composition of claim 11 wherein said glyceryl palmitostearate is present in an amount from about 5% to about 90% by weight of each microparticle.

13.(Original) The rapid absorption pharmaceutical composition of claim 12 wherein said glyceryl palmitostearate is present in an amount from about 15% to about 75% by weight of each microparticle.

14.(Original) The rapid absorption pharmaceutical composition of claim 13 wherein said distilled glyceryl palmitostearate is present in an amount from about 25% to about 45% by weight of each microparticle.

15.(Original) The rapid absorption pharmaceutical composition of claim 14 wherein said distilled glyceryl palmitostearate is present in an amount of about 35% by weight of each microparticle.

16.(Original) The rapid absorption pharmaceutical composition of claim 4 wherein said at least one solubility enhancer is selected from the group consisting of a macrogol fatty acid ester, poloxamer, polyethylene glycol, polyvinylpyrrolidone, sodium lauryl sulfate, and any combination thereof.

17.(Original) The rapid absorption pharmaceutical composition of claim 16 wherein said at least one solubility enhancer is a macrogol fatty acid ester.

18.(Original) The rapid absorption pharmaceutical composition of claim 17 wherein said macrogol fatty acid ester is in an amount greater than from about 0% to about 95% by weight of each microparticle.

19.(Original) The rapid absorption pharmaceutical composition of claim 18 wherein said macrogol fatty acid ester is present in an amount from about 1% to about 50% by weight of each microparticle.

20.(Original) The rapid absorption pharmaceutical composition of claim 19 wherein said macrogol fatty acid ester is present in an amount of from about 5% to about 35% by weight of each microparticle.

21.(Original) The rapid absorption pharmaceutical composition of claim 20 wherein said macrogol fatty acid ester is present in an amount of about 5% by weight of each microparticle.

22.(Original) The rapid absorption pharmaceutical composition of claim 20 wherein said macrogol fatty acid ester is present in an amount of about 35% by weight of each microparticle.

23.(Original) The rapid absorption pharmaceutical composition of claim 17 wherein said macrogol fatty acid ester is selected from the group consisting of Gelucire 50/13, Gelucire 44/14 and any combination thereof.

24.(Original) The rapid absorption pharmaceutical composition of claim 23 wherein said macrogol fatty acid ester is Gelucire 50/13.

25.(Original) The rapid absorption pharmaceutical composition of claim 21 wherein said macrogol fatty acid ester is Gelucire 50/13.

26.(Original) The rapid absorption pharmaceutical composition of claim 22 wherein said macrogol fatty acid ester is Gelucire 50/13.

27.(Currently Amended) The rapid absorption pharmaceutical composition of claim 4 wherein said microparticles are coated with at least one taste-masking ~~coat~~ coating.

28.(Original) The rapid absorption pharmaceutical composition of claim 27 wherein the at least one taste-masking coating is comprised of a combination of at least one hydrophobic polymer and at least one hydrophilic polymer.

29.(Original) The rapid absorption pharmaceutical composition of claim 28 wherein the hydrophobic polymer and hydrophilic polymer is present in a ratio of 7:3 respectively.

30.(Original) The rapid absorption pharmaceutical composition of claim 29 wherein said hydrophobic polymer is Ethylcellulose E45 and said hydrophilic polymer is Povidone K30.

31.(Original) A rapid absorption pharmaceutical composition comprising an effective amount of a selective 5-HT agonist sumatriptan, glyceryl palmitostearate, and a macrogol fatty acid ester.

32.(Original) The rapid absorption pharmaceutical composition of claim 31 wherein said composition is in the form of a plurality of microparticles.

33.(Original) The rapid absorption pharmaceutical composition of claim 32 wherein said microparticles are coated with a taste-masking coating.

34.(Original) The rapid absorption pharmaceutical composition of claim 33 wherein said sumatriptan is about 30% by weight of each microparticle, said glyceryl palmitostearate is

about 65% by weight of each microparticle and said macrogol fatty acid ester is about 5% by weight of each microparticle.

35.(Original) The rapid absorption pharmaceutical composition of claim 34 wherein said macrogol fatty acid ester is Gelucire 50/13.

36.(Original) The rapid absorption pharmaceutical composition of claim 33 wherein said sumatriptan is about 30% by weight of each microparticle, said glyceryl palmitostearate is about 35% by weight of each microparticle and said macrogol fatty acid ester is about 35% by weight of each microparticle.

37.(Original) The rapid absorption pharmaceutical composition of claim 36 wherein said macrogol fatty acid ester is Gelucire 50/13.

38.(Original) The rapid absorption pharmaceutical composition of claim 35 wherein said microparticles are incorporated into a suitable oral dosage form.

39.(Original) The rapid absorption pharmaceutical composition of claim 38 wherein said oral dosage form is selected from the group consisting of a fast-dispersing direct compression non-cushioning matrix tablet, a fast-dispersing direct compression cushioning matrix tablet, a direct compression non-cushioning matrix tablet, a direct compression cushioning matrix tablet, capsule, buccal tablet, and sachet.

40.(Original) The rapid absorption pharmaceutical composition of claim 39 wherein said oral dosage form is a fast-dispersing direct compression non-cushioning matrix tablet.

41.(Original) The rapid absorption pharmaceutical composition of claim 37 wherein said microparticles are incorporated into a suitable oral dosage form.

42.(Original) The rapid absorption pharmaceutical composition of claim 41 wherein said oral dosage form is selected from the group consisting of a fast-dispersing direct compression non-cushioning matrix tablet, a fast-dispersing direct compression cushioning matrix tablet, a direct compression non-cushioning matrix tablet, a direct compression cushioning matrix tablet, capsule, buccal tablet, and sachet.

43.(Original) The rapid absorption pharmaceutical composition of claim 42 wherein said oral dosage form is a fast-dispersing direct compression non-cushioning matrix tablet.

44. - 124. (Cancelled)

125.(Original) The rapid absorption pharmaceutical composition of claim 9 wherein said sumatriptan is present in an amount of about 30% by weight of said microparticle.

126.(Original) The rapid absorption pharmaceutical composition of claim 9 wherein said sumatriptan is present in an amount of about 40% by weight of each microparticle.

127.(Original) The rapid absorption pharmaceutical composition of claim 13 wherein said distilled glyceryl palmitostearate is present in an amount of about 65% by weight of each microparticle.

128.(Original) The rapid absorption pharmaceutical composition of claim 14 wherein said distilled glyceryl palmitostearate is present in an amount of about 35% by weight of each microparticle.

129.(Original) The rapid absorption pharmaceutical composition of claim 14 wherein said distilled glyceryl palmitostearate is present in an amount of about 25% by weight of each microparticle.

130. - 139 (Cancelled)

140. (Previously Presented) The rapid absorption pharmaceutical composition of Claim 1 in combination with at least one flavourant or sweetner.

141. (Previously Presented) The rapid absorption pharmaceutical composition of Claim 31 in combination with at least one flavourant or sweetner.

142. (Previously Presented) The rapid absorption pharmaceutical composition of Claim 27 wherein said taste-masking coating comprises at least one flavourant or sweetner.

143. (Previously Presented) The rapid absorption pharmaceutical composition of Claim 33 wherein said taste-masking coating comprises at least one flavourant or sweetner.

144. (Previously Presented) The rapid absorption pharmaceutical composition of Claim 40 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises at least one flavourant or sweetner.

145. (Previously Presented) The rapid absorption pharmaceutical composition of Claim 43 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises at least one flavourant or sweetner.

146. - 200. (Cancelled)

201. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 140 comprising a flavourant, wherein said flavourant is Intense Peppermint.

202. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 141 comprising a flavourant, wherein said flavourant is Intense Peppermint.

203. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 140 comprising a sweetener, wherein said sweetener is Acesulfame K.

204. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 141 comprising a sweetener, wherein said sweetener is Acesulfame K.

205. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 142 wherein said taste-masking coating comprises a flavourant, and wherein the flavourant is Intense Peppermint.

206. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 143 wherein said taste-masking coating comprises a flavourant, and wherein said flavourant is Intense Peppermint.

207. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 142 wherein said taste-masking coating comprises a sweetener, and wherein said sweetener is a combination of Acesulfame K and Magnasweet® 100.

208. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 143 wherein said taste-masking coating comprises a sweetener, and wherein said sweetener is a combination of Acesulfame K and Magnasweet® 100.

209. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 144 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises a flavourant, and wherein said flavourant is Intense Peppermint.

210. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 145 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises a flavourant, and wherein said flavourant is Intense Peppermint.

211. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 144 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises a sweetener, and wherein said sweetener is a combination of Acesulfame K and Magnasweet® 100.

212. (Currently Amended) The rapid absorption pharmaceutical composition of Claim 145 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises a sweetener, and wherein said sweetener is a combination of Acesulfame K and Magnasweet® 100.

213. - 330. (Cancelled)

331. (New) The rapid absorption pharmaceutical composition of Claim 140 comprising a flavourant, wherein said flavourant is peppermint.

332. (New) The rapid absorption pharmaceutical composition of Claim 141 comprising a flavourant, wherein said flavourant is peppermint.

333. (New) The rapid absorption pharmaceutical composition of Claim 142 wherein said taste-masking coating comprises a flavourant, and wherein the flavourant is peppermint.

334. (New) The rapid absorption pharmaceutical composition of Claim 143 wherein said taste-masking coating comprises a flavourant, and wherein said flavourant is peppermint.

335. (New) The rapid absorption pharmaceutical composition of Claim 144 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises a flavourant, and wherein said flavourant is peppermint.

336. (New) The rapid absorption pharmaceutical composition of Claim 145 wherein said fast-dispersing direct compression non-crushing matrix tablet comprises a flavourant, and wherein said flavourant is peppermint.